



SHUKRA
PHARMACEUTICALS LTD.

Date: June 27, 2025

To,
The Manager – Listing Compliance
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 524632

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Award of Tender by Rajasthan Medical Services Corporation Limited

Dear Sir/Madam,

We are pleased to inform our stakeholders that Shukra Pharmaceuticals Limited has received a Letter of Acceptance dated June 24, 2025, from Rajasthan Medical Services Corporation Limited (RMSCL), signifying the Company's successful bid under Tender Ref No. F.02(412)/RMSCL/PROCUREMENT/DRUG/NIB-10/2024/1396.

Under this tender, the Company has been awarded a Rate Contract cum Supply Agreement for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan. The total contract value aggregates to ₹11.59 Crore, with supplies scheduled to be completed by December 2026.

This prestigious contract reinforces Shukra Pharmaceuticals' reputation as a trusted healthcare partner in the public sector and reflects the Company's growing capabilities in large-scale institutional supply. The Company is currently finalizing the required formalities, including execution of the agreement and submission of the stipulated performance security.

We believe this development will significantly enhance our visibility in the institutional segment and contribute meaningfully to our revenue pipeline over the coming quarters. This achievement aligns with our broader strategic vision of expanding our footprint in government procurement channels and delivering long-term value to our shareholders.

We request you to take the above on record as a material event in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015.

Thanking you,
Yours faithfully,
For Shukra Pharmaceuticals Limited

Dakshesh Shah
Managing Director
DIN: 00561666



CIN : L24231GJ1993PLC019079